24 June 2026

Aurobindo Pharma acquisition of Lannett

This acquisition serves as a practical example of Indian pharmaceutical companies expanding their global footprint and navigating international regulatory frameworks like the FTC, which is relevant context for discussions on industrial policy and liberalization.

Questions

1. Discuss the role of competition authorities in regulating cross-border pharmaceutical acquisitions to ensure market stability and consumer welfare. 150 words
   Attempt this — 150 words in 8 min

   0 / 150 words 8:00 Reset
2. The expansion of Indian pharmaceutical firms into global markets through strategic acquisitions presents both opportunities for growth and challenges regarding regulatory compliance. Analyze the implications of international antitrust regulations on the global footprint of the Indian pharmaceutical industry. 250 words
   Attempt this — 250 words in 11 min

   0 / 250 words 11:00 Reset

Prelims

1. Which regulatory body granted approval for the acquisition of Lannett Company by Aurobindo Pharma?

   1. A Food and Drug Administration (FDA)
   2. B Department of Justice (DOJ)
   3. C Federal Trade Commission (FTC)
   4. D Securities and Exchange Commission (SEC)

2. What was the primary reason for the FTC requiring the divestiture of four generic products in the Aurobindo-Lannett deal?

   1. A To facilitate the entry of new domestic competitors into the Indian market
   2. B To improve the quality of the drugs being manufactured
   3. C To prevent the exercise of unilateral market power and potential price increases
   4. D To comply with local environmental regulations in Pennsylvania